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Abstract: Multidrug resistance (MDR) that occurs in cancer cells constitutes one of the major reasons
for chemotherapy failure. The main molecular mechanism of MDR is overexpression of protein
transporters from the ATP-binding cassette (ABC) superfamily, such as ABCB1 (multidrug resistance
protein 1 (MDR1), P-glycoprotein). At the expense of ATP hydrolysis, ABCB1 pumps a diverse
range of substrates (including anticancer drugs) out of the cell, thereby reducing their intracellular
concentration. In the present study, the ability of two patented disiloxanes (SILA-409 and SILA-421) to
reverse drug resistance in human colon adenocarcinoma cell lines LoVo and LoVo/Dx was investigated.
It was demonstrated that both compounds in concentrations of 0.5–1 µM strongly increased the
sensitivity of LoVo/Dx cells to doxorubicin. By means of an accumulation test in which rhodamine
123 was used as an ABCB1 substrate analogue, both organosilicon compounds were also shown to
inhibit ABCB1 transport activity. The intracellular accumulation of doxorubicin was also increased,
and more drug entered the cellular nuclei of resistant cells in the presence of the studied compounds.
In conclusion, both SILA-409 and SILA-421 were demonstrated to be effective MDR reversal agents in
resistant human colon cancer cells.
Keywords: organosilicon compounds; SILA-409 (Alis-409); SILA-421 (Alis-421); multidrug resistance
(MDR) reversal; ABCB1 (P-glycoprotein); colon cancer
1. Introduction
Since chemotherapy continues to be a method of choice for the treatment of various types of
cancer, any factors that undermine its effectiveness constitute a serious therapeutic issue. In the
majority of patients, the initial response to chemotherapy is satisfactory; however, the occurrence of
multidrug resistance (MDR) during treatment results in a development of progressive disease [1,2].
Cells displaying the MDR phenotype are no longer vulnerable to cytotoxic actions of many functionally
and structurally dissimilar anti-cancer drugs.
Among several mechanisms that may lead to the development of MDR, the overexpression of
ATP-binding cassette (ABC) transporters such as ABCB1 (P-glycoprotein, MDR1: multidrug resistance
protein 1), ABCC1 (MRP1: multidrug resistance-associated protein 1), and ABCG2 (BCRP: breast
cancer resistance protein) proteins seems to prevail [3,4]. It was recently reported that non-ABC
transporters such as Hedgehog receptor Patched were also engaged in doxorubicin (Dox) efflux and
conferred Dox resistance to cancer cells [5,6]. ABCB1 is a transporter that utilizes the energy gained
Molecules 2020, 25, 1654; doi:10.3390/molecules25071654 www.mdpi.com/journal/molecules
Molecules 2020, 25, 1654 2 of 14
from the hydrolysis of ATP to pump many structurally variable substrates (including xenobiotics and
chemotherapeutics) out of the cell [7]. Among the numerous strategies proposed to overcome MDR,
the most basic approach is the idea to use the inhibitor of a multidrug transporter (MDR modulator)
along with chemotherapy in hopes to increase the intracellular accumulation of an anti-cancer drug
and to improve the outcome of the treatment. Although this approach is yet to result in any clinical
success [8–10], the search for new substances that could serve as clinically applicable MDR modulators
is continuously ongoing.
Silicon is a metalloid, which is a group of chemical elements also called semi-metals [11]. It can
form chemical bonds with carbon and oxygen, and silicon-containing compounds are widely used in
medicine and engineering. Silicone is a synthetic polymer composed of repeating siloxane units. Due
to its high biocompatibility and favorable mechanical properties, silicone is used for the production of
various medical implants (e.g., breast or testicle), as well as contact lenses [11]. On the other hand, silica
materials are applied as controlled drug delivery systems and three-dimensional scaffolds for tissue
engineering [11]. The introduction of a silicon atom to a structure usually yields a molecule of higher
lipophilicity than its carbon analogue. The increased anti-cancer activity of silicon–indomethacin
derivatives was recorded, and it was claimed that the higher lipophilicity of silicon derivatives resulted
in their increased uptake by cancer cells [12]. New sila-organosulfur compounds were recently
synthesized that were reported to be effective anti-cancer and antibacterial agents [13].
SILA-409 and SILA-421 are water-soluble disiloxanes that were synthesized and patented as
putative MDR modulators [14]. They were previously demonstrated to increase fluorescent dye
accumulation in human ABCB1 gene-transfected mouse lymphoma cells and, to much lesser extent,
in colon carcinoma Colo320/MDR1-LRP cells, but not in ABCC1 expressing breast cancer (HTB-26/MRP1)
and stomach cancer (257P/MDR) cells, which was attributed to their specific interactions with the
ABCB1 transporter [15]. The specificity of disiloxanes toward ABCB1 was corroborated in a study by
Kars et al. conducted in a model system of breast cancer cells [16]. Recently, the synergism between
disiloxanes and amyloid β-protein in the inhibition of ABCB1 transporter activity was reported [17].
In an in vivo study on mice bearing human pancreatic cancer xenografts, the application of SILA-409
resulted in the reduction of tumor growth that was accompanied by increased apoptosis and a reduced
level of ABCB1 protein in cancer cells [18]. SILA-421 was found to cause cell-cycle arrest and apoptosis
in several non-MDR cancer cell lines [19]. The analysis of the global gene expression profile of HL-60
leukemia cells treated with this compound revealed multiple cellular pathways affected by SILA-421,
including DNA replication and transcription processes. Interference with these processes was also
attributed to the antimicrobial activity of SILA-409 and SILA-421 compounds [20–22], as well as their
ability to eliminate resistance-bearing plasmids from Escherichia coli strains [23]. Additionally, the weak
chemopreventive activity of disiloxanes was reported both in vitro and in vivo [24].
In the present work, the ability of SILA-409 and SILA-421 to reverse Dox resistance in human
adenocarcinoma cells LoVo/Dx was demonstrated. The disiloxanes inhibited the transport function of
ABCB1 protein both in LoVo/Dx cells and in Madin-Darby Canine Kidney (MDCK) cells expressing
human ABCB1 (MDCK-MDR1). The amount of Dox accumulated inside LoVo/Dx cells was also
elevated in the presence of studied compounds, and its distribution pattern was changed.
2. Results and Discussion
2.1. Cytotoxicity of Disiloxanes
A human adenocarcinoma cell line sensitive to Dox (LoVo) and its Dox-resistant counterpart
(LoVo/Dx) were employed as a model system. It was previously demonstrated that the increased
expression of ABCB1 transporter is mainly responsible for the resistance of LoVo/Dx cells [25].
The cytotoxicity of both SILA-409 and SILA-421 to LoVo and LoVo/Dx cells was comparable (Figure 1).
Both compounds were strongly cytotoxic to the cells in concentrations above 10 µM. The half maximal
inhibitory concentration (IC50) values of SILA-409 were 15.6 µM and 24.6 µM for LoVo and LoVo/Dx
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cells, respectively. For SILA-421, IC50 values were 8.4 µM in LoVo cells and 9.2 µM in LoVo/Dx cells.
SILA-421 was more toxic than SILA-409, which might be the result of the higher lipophilicity of
this compound.
Figure 1. Cytotoxicity of SILA-409 (A) and SILA-421 (B) to LoVo (open symbols) and LoVo/Dx cells
(full symbols). Means of three experiments ± SD are presented.
The cytotoxicity of both disiloxanes to MDCK cells and MDCK transfected with human ABCB1 gene
(MDCK-MDR1) was similar (Figure S1, Supplementary Materials). Both compounds in concentrations
below 5 µM slightly stimulated cell growth, whereas, in concentrations of 25 µM and higher, <10% of
cells survived. IC50 values of SILA-409 in MDCK and MDCK-MDR1 cells were 14.2 µM and 13.9 µM,
respectively. For SILA-421, the values of 11.6 µM and 12.1 µM were analogously recorded. Similarly to
the findings in colon cancer cells, IC50 values for SILA-421 were slightly lower than those for SILA-409.
The cytotoxicity of the studied disiloxanes to various cancer cell lines reported previously [15,19]
was similar to the results of the present study. The IC50 values of SILA-421 analyzed in several various
cancer cell lines, as well as in normal cells HEK-293, lay within the range 5–35 µM [19]. In another
study, the cytotoxicity of both SILA-409 and SILA-421 was assessed in a panel of multidrug resistant
cancer cell lines of different patterns of expression of MDR-associated transporters [15]. IC50 values
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varied from 8–80 µM depending on cell line. In three out of five cell lines studied, SILA-421 was found
to be slightly more cytotoxic than SILA-409.
The analysis of the disiloxanes’ chemical structures (Figure S3, Supplementary Materials) and
the calculation of their theoretical logP values, performed using the free web tool Molinspiration
(https://www.molinspiration.com/cgi-bin/properties), demonstrated that SILA-421 was more lipophilic
than SILA-409 (logP values were 5.83 and 9.60 for SILA-409 and SILA-421, respectively). Lipophilicity
was observed to positively correlate with the antiproliferative activity of various compounds toward
cancer cells [26,27]. However, in other experimental settings, molecular parameters other than
lipophilicity were found to affect cytotoxicity to the highest extent [28,29]. Therefore, a larger series
of disiloxanes and a characterization of more of their molecular descriptors would be required to
determine the effect of lipophilicity on the biological activity of these compounds.
2.2. Influence of Disiloxanes on Doxorubicin Cytotoxicity
Next, the influence of the studied modulators on Dox cytotoxicity was investigated (Figure 2).
SILA-409 and SILA-421 were applied in concentrations in which they killed <10% of LoVo/Dx cells.
The treatment of cells with a combination of either SILA-409 or SILA-421 with Dox significantly reduced
the survival rate of resistant colon cancer cells, i.e., the disiloxanes partially reversed Dox resistance.
Non-toxic concentrations of SILA-409 and SILA-421 were applied together with doxorubicin. Sensitive
LoVo cells were more vulnerable to this anticancer drug (IC50 Dox = 4.0µM) than ABCB1-overexpressing
LoVo/Dx cells (IC50 Dox = 30.0 µM) [30]. It was demonstrated that both compounds strongly increased
the sensitivity of LoVo/Dx cells to doxorubicin without changing the sensitivity of LoVo cells to
this drug. The value of IC50 for Dox was reduced to 5.7 µM in the presence of SILA-409 at 0.5 µM
concentration, and to 6.1 µM in the presence of SILA-421 (1 µM). The isobolographic analysis applied
to the obtained results revealed the existence of synergism between Dox and each of the studied
disiloxanes (Table 1).
Table 1. Combination of disiloxanes with Dox against LoVo/Dx cell growth.
Concentration (µM) Ratio Combination Index
Dox SILA-409
8.62 0.5 17.24:1 0.7772
17.24 0.5 34.48:1 0.6136
SILA-421
8.62 1 8.62:1 0.6467
17.24 1 17.24:1 0.5632
Dose and effect data were obtained from the sulforhodamine B (SRB) assay (mean values of three experiments) and
subjected to CompuSyn analysis. CI (combination index) values were generated by CompuSyn software. CI = 1
indicates additive effect, CI < 1 indicates synergism, and CI > 1 indicates antagonism.
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Figure 2. The changes in doxorubicin (Dox) cytotoxicity in LoVo (circles) and LoVo/Dx cells (squares)
caused by SILA-409 at 0.5 µM (A) and SILA-421 at 1 µM (B). Open symbols represent cells treated with
Dox only, whereas full symbols represent cells treated with Dox and the modulator. Means of three
experiments ± SD are presented.
The reduction of Dox cytotoxicity by SILA-409 and SILA 421 was previously observed in human
ABCB1 gene-transfected mouse lymphoma cells (L5718/MDR) and the resistant colon cancer cell line
(Colo320/MDR1-LRP) [15]. Synergism between disiloxanes and Dox was observed in these cell lines
but not in breast cancer cell lines MCF-7, T47-D, and HTB-26/MRP1. The authors concluded that
the presence of a functional ABCB1 transporter was essential for disiloxanes to be able to revert Dox
resistance [15]. This pointed to the specific interactions between SILA-409 and SILA-421 and ABCB1
protein. Similar synergistic interactions with appropriate anticancer drugs were also observed for
SILA-409 and SILA-421 in MCF-7 cell lines resistant to paclitaxel and docetaxel, but not in the sublines
resistant to Dox and vincristine [16].
Dox cytotoxicity was significantly lower (p < 0.05) in LoVo/Dx than in LoVo cells as determined by
Student’s t-test. Significant enhancement (p < 0.05) of Dox cytotoxicity was recorded for both SILA-409
and SILA-421in LoVo/Dx cells in the whole concentration range
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2.3. Intracellular Accumulation of Rhodamine 123 (R123)
Rhodamine 123 (R123) is popularly used as a fluorescent reporter substrate of the ABCB1
transporter. Both SILA-409 and SILA-421 caused an increase in R123 accumulation in LoVo/Dx and
MDCK-MDR1 cells (Figure 3) in a concentration-dependent manner, which suggested that both
compounds were inhibitors of ABCB1 transport activity. SILA-421 seemed to exert its inhibitory action
in lower concentrations than SILA-409, which significantly elevated fluorescence intensity ratio (FIR)
values only in concentrations above 10 µM in Dox-resistant colon cancer cells.
Figure 3. The influence of SILA-409 (gray) and SILA-421 (white) on R123 intracellular accumulation in
LoVo/Dx (A) and Madin-Darby Canine Kidney-multidrug resistance protein 1 (MDCK-MDR1) cells
(B). Means ± SD of three experiments are presented. The statistically significant differences from the
untreated cells were determined using Student’s t-test (* p < 0.05).
Molecules 2020, 25, 1654 7 of 14
Molnar et al. [15] also observed increased R123 accumulation in human ABCB1 gene-transfected
mouse lymphoma cells (L5718/MDR) treated with SILA-409 and SILA-421 in concentrations up to
2 µg/mL. Both compounds demonstrated similar activity in this respect. They were, however, unable
to affect R123 accumulation in sensitive breast and prostate cancer cells and it was again concluded
that the activity of disiloxanes can only be observed in cell lines that express a functional ABCB1
transporter [15]. In the study of Kars et al. [16], both disiloxanes were demonstrated to increase
R123 accumulation in a series of breast cancer cell lines resistant to paclitaxel, docetaxel, Dox, and
vincristine. In contrast to our findings, SILA-409 was observed to be more active then SILA-421 in this
experimental setting.
2.4. Intracellular Accumulation of Doxorubicin
Accumulation of Dox itself by human colon cancer cells was also investigated. As presented
in Figure 4, drug-sensitive LoVo cells accumulated more drug than Dox-resistant LoVo/Dx cells.
The treatment of cells by disiloxanes at a concentration of 5 µM resulted in a significant increase in Dox
accumulation by LoVo/Dx cells with apparently no effect observed in LoVo cells.
Figure 4. Intracellular doxorubicin (Dox) accumulation in LoVo (gray bars) and LoVo/Dx cells (white
bars) treated with SILA-409 and SILA-421 at 5 µM concentration. Means ± SD of three experiments are
presented. The statistically significant differences between untreated and disiloxane-treated cells were
determined using Student’s t-test (* p < 0.05).
Since Dox is characterized by strong intrinsic fluorescence, its intracellular accumulation may
also be examined directly by means of fluorescence microscopy. Again, LoVo cells accumulated
more Dox than LoVo/Dx cells (Figure 5 and Figure S2, Supplementary Materials), and the application
of disiloxanes at a concentration of 5 µM resulted in an increase in accumulation of the drug in
Dox-resistant cells but not in the sensitive ones. SILA-421 was more effective in this respect than
SILA-409. The intracellular distribution of Dox was also affected by organosilicon compounds. Dox that
was excluded from the nuclei of untreated resistant cells was demonstrated to localize within these
organelles in modulator-treated LoVo/Dx cells.
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Figure 5. Intensity of intracellular fluorescence of Dox, measured by ImageJ software, in LoVo (gray
bars) and LoVo/Dx cells (white bars) treated with 5 µM of SILA-409 and SILA-421 is presented as
the mean fluorescence values ± SD measured in 20 representative cells. The statistically significant
differences from the untreated cells were determined using Student’s t-test (* p < 0.05).
According to our best knowledge, the influence of SILA-409 and SILA-421 on Dox accumulation
and cellular localization was not previously studied. The pattern of changes in Dox accumulation
caused by disiloxanes was similar to the changes caused by verapamil (a well-known inhibitor of
ABCB1 protein) observed previously in the same colon cancer cell lines as those used in the present
work [25].
2.5. Expression of ABCB1 Transporter
Additionally, the influence of disiloxanes on ABCB1 transporter expression was analyzed by
Western blotting (Figure 6). Both SILA-409 and SILA-421 significantly decreased ABCB1 protein level
in LoVo/Dx cells during 48 h of treatment. SILA-421 turned out to be more active in this respect in
comparison with SILA-409. No effect of organosilicon compounds on ABCB1 protein level was noted
during 60 min of treatment with modulators (data not shown).
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Figure 6. Western blot analysis of ATP-binding cassette B1 (ABCB1) protein level (A) in LoVo/Dx
cells cultured with 0.5 µM SILA-409 and SILA-421 for 48 h. The molecular masses of the proteins are
indicated on the left side of the gel. β-Glucuronidase (β-GUS) was used as a reference protein. The
relative level of ABCB1 expression (B) was normalized to the control derived from non-treated LoVo/Dx
cells. The results of three experiments ± SD are presented. The statistically significant differences from
the untreated controls were determined using Student’s t-test (* p < 0.05).
The downregulation of ABCB1 expression was previously demonstrated using
immunohistochemical methods in pancreatic tumor samples isolated from mice treated with
SILA-409 [18]. On the other hand, no influence of disiloxanes (tested in concentrations of 380–500µg/mL)
on ABCB1 expression level was detected in mouse T-lymphoma cells transfected with human
ABCB1 [15].
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3. Materials and Methods
3.1. Chemicals
Orgasnosilicon compounds 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-bis(3-morpholino-propyl)disiloxan
dihydrochloride (SILA-409) and 1,3-dimethyl-1,3-bis(4-fluorophenyl)-1,3-
bis{3-[1(4-butylpiperazinyl)]-propyl}-disiloxan tetrahydrochloride (SILA-421) were synthesized and
patented [14]. Their chemical structures are presented in Figure S3 (Supplementary Materials). Stock
solutions of organosilicon compounds were prepared in dimethyl sulfoxide (DMSO). Sulforhodamine
B (SRB), rhodamine 123 (R123), and doxorubicin (Dox) were obtained from Sigma-Aldrich (Poznan,
Poland) and dissolved in water.
3.2. Cell Culture
Human colorectal adenocarcinoma cell line, LoVo, and its resistant subline, LoVo/Dx, obtained by
prolonged exposure to Dox [31], were obtained from the Institute of Immunology and Experimental
Therapy of Polish Academy of Science (Wroclaw, Poland). Cultivation conditions were Ham’s F12
medium (with the addition of 10% fetal bovine serum, l-glutamine, antibiotics, and, in the case of
LoVo/Dx cells, Dox at 100 ng/mL), at 37 ◦C and 5% CO2.
Madin-Darby Canine Kidney cells (MDCK) and MDCK cells expressing human ABCB1
(MDCK-MDR1) [32] were purchased from the Netherlands Cancer Institute (NKI-AVL, Amsterdam,
the Netherlands). The cells were cultured in DMEM medium supplemented with 10% fetal bovine
serum, l-glutamine, and antibiotics at 37 ◦C and 5% CO2.
3.3. Cell Viability Assay
The SRB assay [33] with minor modifications was used for the estimation of the effect of the
studied compounds on cell growth. Cells were seeded in 96-well flat-bottom microtiter plates in 75 µL
of medium and allowed to attach (60 min, 37 ◦C). Then, 75 µL of medium containing an amount of
the studied compounds (such that a desired compound concentration was obtained in a final sample
volume) was added to each well, with the exception of the control wells, which contained medium
only. The culture plates were then incubated for 48 h at 37 ◦C. The further procedure was carried out
as previously described [34]. Cytotoxicity of DMSO to LoVo and LoVo/Dx cells was negligible.
3.4. Isobolographic Analysis
Combination index (CI) values were calculated using the CompuSyn software (www.combosyn.
com, ComboSyn, Inc., Paramus, USA) according to the classic median-effect equation as described by








where (Dx)1 is the dose of drug 1 alone that inhibits a system by x%, (Dx)2 is the dose of drug 2 alone
that inhibits a system by x%, and (D)1 + (D)2 are doses of drugs 1 and 2 in combination that also inhibit
a system by x%.
3.5. Accumulation of Rhodamine 123 in Cancer Cells
In order to determine R123 accumulation, the cells were harvested and incubated (300,000 cells/mL)
with the appropriate concentration of the studied compound (15 min; 25 ◦C). Next, R123 (10 µM) was
added, and the cells were incubated for 60 min at 37 ◦C. After centrifugation, the samples were washed
twice with ice-cold phosphate-buffered saline (PBS) and dissolved in lysis buffer (20 mM Tris-HCl,
0.2% SDS, pH = 7.7). Intracellular fluorescence (λex = 485 nm, λem = 538 nm) was collected with the use
of an Infinite M200Pro plate reader (Tecan Instruments, Maennedorf, Switzerland). Based on measured
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the fluorescence intensity (FL) of the treated and control samples (without modulator), the fluorescence
intensity ratio (FIR) was calculated according to the following equation:
FIR =
(FLLoVoDx or MDCK−MDR1 treated)/(FLLoVoDx or MDCK−MDR1 control)
(FLLoVo or MDCK treated)/(FLLoVo or MDCK control)
. (2)
3.6. Intracellular Accumulation of Doxorubicin
Intracellular Dox accumulation was detected with a fluorimetry based assay as described
previously [36]. Briefly, cells were seeded (800,000/well) onto a six-well plate and incubated for
24 h at 37 ◦C. Then, the cells were incubated in PBS containing Dox (4 µM) and treated with the
modulators. After 48 h of incubation, cells were washed twice in ice-cold PBS and detached. Next,
cells were centrifuged and lysed. The cellular protein content was determined using the standard
method of Bradford reaction [37]. Dox content was measured using an LS-5 spectrofluorimeter
(Perkin-Elmer, Beaconsfield, UK). Excitation and emission wavelengths were 475 and 553 nm,
respectively. Fluorescence was expressed in ng of Dox per mg of cellular protein with the use
of the calibration curve prepared previously.
For fluorescence microscopic experiments, LoVo and LoVo/Dx cells were cultivated on eight-well
µ-Slide microscopy chambers (Ibidi, Munich, Germany) for 48 h. For the experiment, a fresh portion
of F12 medium was added containing 50 µM Dox (plus 5 µM of the studied compounds in treated
samples), and cells were incubated for 60 min at 37 ◦C. After incubation, the chambers were washed
with PBS and with serum- and phenol red-free F12 medium. The images were collected with a Nikon
Eclipse TE2000-E microscope. Fluorescence was excited in the range 528–553 nm and collected in the
range 578–633 nm.
3.7. Expression of ABCB1 Protein
Cell lysates were prepared in ice-cold lysis buffer (1% Triton X-100, 50 mM Hepes, 150 mM NaCl,
1.5 mM MgCl2, 1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA),
1 mM phenylmethylsulfonyl fluoride (PMSF), 100 mM NaF, 10 mM sodium pyrophosphate, 10 µg/mL
aprotinin, and 10% glycerol, pH 7.4). After centrifugation of whole-cell lysates (13,000× g, 10 min,
4 ◦C), the supernatants were taken for analysis. The standard method of Bradford reaction was used to
measure protein content (Bradford, 1976). The proteins were subjected to SDS-PAGE, transferred to
polyvinylidene difluoride (PVDF) membranes, and detected using primary antibodies in tris-buffered
saline with Tween (TBS-T) buffer (0.1% Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, 1, pH 7.4) with 5%
bovine serum albumin (BSA). The anti-ABCB1 mouse monoclonal primary antibodies (C494) (Alexis)
were used at dilution 1:1000. The level of β-glucuronidase (β-GUS) was also determined as a reference
protein (anti-glucuronidase mouse monoclonal antibody, diluted 1:1000, Thermo Scientific). After
incubation (overnight at 4 ◦C), the membranes were washed in TBS-T and incubated with rabbit
anti-mouse immunoglobulin G (IgG) secondary antibody conjugated to horseradish peroxidase (HRP)
(dilution 1:1000, Thermo Scientific) for 30 min at 4 ◦C. The membranes were then washed with TBS-T,
and the proteins were visualized. The relative amount of protein normalized to the control (non-treated
cells) was determined. The optical density of the bands on the electrophoregram was detected with the
Image J softwar version 1.43m.
3.8. Statistical Analysis
Data represent the means ± standard deviation (SD) of at least three replications. Student’s t-test
was applied, and p-values less than 0.05 were considered to be statistically significant.
4. Conclusions
Organosilicon compounds, SILA-409 and SILA-421, were demonstrated to reverse doxorubicin
resistance in a human colon cancer cell line. Both compounds were inhibitors of the transport
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function of ABCB1 protein judging from the increased accumulation of R123 by modulator-treated
cells. Intracellular accumulation of Dox was also increased, and more drug entered cellular nuclei in
the presence of the studied compounds. SILA-421 demonstrated slightly higher activity than SILA-409.
Additionally, the decreased expression of ABCB1 protein after treatment with disiloxanes was recorded.
Therefore, the studied compounds acted as resistance-reversing agents via two mechanisms. They were
effective inhibitors of the ABCB1 transport function, and its reduction was easily observed after 60
min of disiloxane treatment (e.g., in fluorescence microscopy and R123 accumulation experiments).
Moreover, after prolonged treatment with SILA-409 and SILA-421, the reduction of ABCB1 protein
level that occurred certainly increased the MDR-reversing potency of these compounds. In conclusion,
both SILA-409 and SILA-421 were demonstrated to be effective anti-MDR agents in resistant human
colon cancer cells.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/25/7/1654/s1:
Figure S1: Cytotoxicity of SILA-409 (A) and SILA-421 (B) to MDCK (full symbols) and MDCK-MDR1 cells (open
symbols). Means of three experiments ± SD are presented; Figure S2: Fluorescence microscopy images illustrating
doxorubicin accumulation in LoVo (A) and LoVo/Dx (B) cells treated with 5 µM SILA-409 (C and D for LoVo and
LoVo/Dx, respectively) and with 5 µM SILA-421 (E and F). Scale bar is 50 µm. Illumination conditions were the
same for all images; Figure S3: Chemical structures of SILA-409 and SILA-421.
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